Prescription Drug Utilization and Spending by Race, Ethnicity, Payer, Health Condition, and US State

Maitreyi Sahu, Joseph L. Dieleman(Institute for Health Metrics and Evaluation), Jonathan D. Campbell(National Health Council), Rayan K. Salih(National Health Council), Azalea Thomson(Institute for Health Metrics and Evaluation), Annie Haakenstad(University of Washington), Sawyer W Crosby, Haley Lescinsky(Institute for Health Metrics and Evaluation), Tyler D. Wagner(National Health Council), John W. Scott(Harborview Medical Center), Andy Stergachis(University of Washington), Maxwell Weil(Institute for Health Metrics and Evaluation), Kayla Taylor(University of Miami), Utibe R. Essien(University of California, Los Angeles), Drew DeJarnatt(Institute for Health Metrics and Evaluation), Laura Dwyer‐Lindgren(Unknown)
JAMA Health Forum
August 8, 2025
10.1001/jamahealthforum.2025.2329
Cited by 2

Related Papers

US Health Care Spending by Payer and Health Condition, 1996-2016
|JAMA|2020|1.3k
Global, regional, and national prevalence and mortality burden of sickle cell disease, 2000–2021: a systematic analysis from the Global Burden of Disease Study 2021
|The Lancet Haematology|2023|674
Measuring the availability of human resources for health and its relationship to universal health coverage for 204 countries and territories from 1990 to 2019: a systematic analysis for the Global Burden of Disease Study 2019
|The Lancet|2022|414
Mapping under-5 and neonatal mortality in Africa, 2000–15: a baseline analysis for the Sustainable Development Goals
|The Lancet|2017|311
Postmenopausal Estrogen Replacement Therapy and the Risk of Alzheimer's Disease: A Population-based Case-Control Study
|American Journal of Epidemiology|1994|303